Tools We Use: Advanced Analytics / Dashboards
Using tools such as Tableau and other BI tools, we create client specific dashboards that visually highlight key performance data. For example, we have created dashboards that combine on-going clinical trials and upcoming clinical trials with current and expected enrollment levels. Such analytics has led to a dramatic reduction in the number of non-performing trials, in the time to open trials and in increasing enrollment in existing trials.
“Observations on Clinical Research: Some Ideas for NHLBAC”, National Heart, Lung Blood Advisory Council, NIH.
“A Model for Evaluating the Efficiency and Effectiveness of Clinical Research,” Medical Executive Committee, NIH, Bethesda
Other Work Related to Advanced Analytics / Dashboards
1. Parker C, Snyder R, Jefford M, Dilts DM, Wolfe R, Millar J (2017) “A Randomized Control Trial of an Additional Funding Intervention to Improve Clinical Trial Enrollment”, J of the National Comprehensive Cancer Network (JNCCN),15(9): 1104-1110. PMID: 28874595
2. Dilts DM, Zell A, Orwoll E (2015) “A Novel Approach to Measuring Efficiency of Scientific Research Projects: Data Envelopment Analysis.” Clinical and Translational Science. 8(5):495-501. PMID:26243147
3. Dilts DM, (2013) “A 3+1 Level Evaluation Model for CRM”, Evaluation & the Health Professions 36(4):464-477 PMID: 23908383.
4. Grazier KL, Trochim W, Dilts DM, Kirk R (2013) “Estimating Return on Investment in Translational Research: Methods and Protocols”, Evaluation & the Health Professions, 36(4):478-491. PMID: 23925706
5. Hirsh BR, Califf RM, Cheng SK, Tasneem A, Horton J, Chriswell K, Schulman KA, Dilts DM, and Abernethy AP (2013) “Design of Oncology Clinical Trials: Insights from a Systematic Analysis of ClinicalTrials.gov,” JAMA Internal Medicine, 173(11):972-979. PMID:23699837.
6. Dilts DM, Rosenblum D, and Trochim WM, (2012) “A Virtual National Laboratory for Re-Engineering Clinical and Translational Science,” Science Translational Medicine, 4(118) 118cm2. PMID:22277966.
7. Massett H, Parreco LK, Padberg RM, Richmond ES, Rienzo, ME, Ryan Leonard CE, Quesenbery W, Killam HW, Johnson, and Dilts DM (2011) “AccrualNet: Addressing low accrual via a knowledge-based, community of practice Platform,” J of Oncology Practice, 7(6): e32-e39. PMID:22379429.
8. Kitterman, D, Cheng, S, Dilts DM, and Orwoll, ES, (2011) “The Prevalence and Economic Impact of Low Enrolling Clinical Studies at an Academic Medical Center,” Academic Medicine 86(11): 1360-66. PMID:21952064
9. Cheng S, Dietrich M, Dilts DM (2011) “Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP Sponsored Clinical Trials,” Clin Cancer Res. 17: 1947-55. PMID:21447723
10. Dilts DM, Cheng S, Crites JS, Sander AB, Doroshow J, (2010) “Phase III Clinical Trial Development: A Process of Chutes & Ladders,” Clin Cancer Res. 16(22): 5381-89. PMID:21062928
11. Cheng S, Dietrich M, Dilts DM (2010) “A Sense of Urgency: Evaluating the Link Between Clinical Trial Development Time and the Accrual Performance of CTEP-Sponsored Studies,” Clin Cancer Res, 16(22): 5557-63. PMID:21062929
12. Dilts DM, Sander AB, Cheng S, Crites J, Ferranti L, Wu, A, Finnigan S., Friedman S, Mooney M, Abrams J, (2009) “The Steps and Time to Process Phase III Clinical Trials at the Cancer Therapy Evaluation Program,” J of Clin Oncol, 27(11): 1761-6. PMID: 19255315
13. Dilts DM, Ridner, SH, Franco A, Murphy B, (2009) “Patients with Cancer and E-mail: Implications for Clinical Communication,” J of Supportive Care in Cancer, 17(8): 1049-1056. PMID:19050941.
14. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Gray R, MacDonald J, Marinucci D, Comis R. (2008) “Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Group,” Clin Cancer Res, 14(11):3427-33. PMID: 18519773
15. Dilts DM and Sandler AB, (2006) “The “Invisible” Barriers to Clinical Trials: The impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials,” J Clin Oncol, 24(28): 4545-52. PMID: 17008693
16. Dilts DM, Sandler AB, Baker M, Cheng S, George SL, Karas KS, McGuire S, Menon G, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL (2006) “Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of the Cancer Leukemia Group B (CALGB), J Clin Oncol, 24(28): 4553-57. PMID: 17008694
17. Xie Bin, Dilts DM and Shor, M (2006) “The Physician-Patient Relationship: The Impact of Patient-Obtained Medical Information,” Health Econ, 15(8): 813-833. PMID: 16550612
18. Hackett SM, and Dilts DM (2004) “A Real Options-Driven Theory of Business Incubation,” J of Technology Transfer, 29(1): 41-54. [Reprinted in “Recent Development in the Economics of Science and Innovation”, editor: A. N Link and C. Antonelli, 2013]
19. Zhang Yong and Dilts DM, (2004) “System Dynamics of Supply Chain Network Organization Structure,” Information Systems and e-Business Management: Special Issue on Supply Chain Management, 2:187-206.
20. Khamalah J and Dilts DM (2001) “Determining Resource Needs for Specialty Ambulatory Clinics using Classification/Assignment Methods,” Int J of Operations and Quantitative Management, 7(4): 241-256.
21. Dilts DM (2001) “Functional Manager’s Perceptions of Performance Measurements: The Impact of Industry and Firm Level Characteristics,” Int J of Agile Manufacturing, 4(1): 17-28.
22. Dilts DM and Khamalah J (1999) “A comparison of ordinal analysis techniques in medical resource usage research,” Electronic Notes in Discrete Mathematics. (http://www.elsevier.com/cas/tree/store/ disc/sub/endm/store/disc2/disc2005.ps) (invited), 2: 51-68
23. Hill T, Menda R, and Dilts DM. (1998) “Using Product Profiling to Illustrate Manufacturing-Marketing Misalignment,” Interfaces, 28(4): 47-63.
24. Menda, R, and Dilts DM, (1997) “The Manufacturing Strategy Formulation Process: Linking Multifunctional Viewpoints,” J of Operations Management, 15(4): 223-41.
25. Doughty MJ, Dilts DM, and Lyle, WM, (1996) “Impact of Using Weighted Versus Unweighted Measures for Assessments of Optometry Faculty Productivity in Research,” J of the Am Optometric Association, 67(7): 410-420. PMID: 8888867
26. Khamalah J, Dilts DM, and Plotkin AD, (1995) “Using Cluster Analysis For Medical Resource Decision Making,” Medical Decision Making, 15(4, Oct-Dec): 333-347. PMID: 8544677
27. Dilts DM, Khamalah J, and Plotkin AD, (1994) “Clinical Low Vision Resource Usage Prediction,” Optometry & Vision Science, 71(7): 422-436. PMID: 7970557
28. Wu W, and Dilts DM (1992) “Integrating Diverse CIM Data Bases: The Role of Natural Language Interface,” IEEE Trans on Systems, Man, & Cybernetics, 22(6): 1331-47.
29. Dilts DM and Wu W, (1991) “Using Knowledge-Based Technology to Integrate CIM Databases,” IEEE Trans on Knowledge & Data Engineering, 3(2): 237-45.
30. Dilts DM, Boyd N, and Whorms H, (1991) “The Evolution of Control Architectures for Automated Manufacturing Systems,” J of Manufacturing Systems, 10(1): 79-93.
31. Yee, D, (34 others) (2012) “Adaptive trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development,” J of Clin Onc, Letter, Dec 20; 30(36): 4584-6. doi: 10.1200/JCO.2012.44.1022
32. Dilts DM, Cheng SK (2012) “The Importance of Doing Trials Right While Doing The Right Trials,” Clin Cancer Res, 18(1):3-5. PMID:22072734
33. Dilts DM, (2010) “US cancer trials may go the way of the Oldsmobile,” Nature Medicine 16(5):21. PMID:20526311
34. Dilts DM, (2010) “An Early Warning: Ailing Canary in the Mine,” J Clin Onc, 28(24): 3799-800. PMID: 20644096
35. Ferranti, L, Cheng S, and Dilts DM (2010) “On Baseball, Medical Decision Making and Innumeracy,” Chapter 18 in Decision Making Wiley, (editors: P Nutt and D Wilson).
36. Pathak SD and Dilts DM (2006) “Investigating evolution in the US healthcare industry,” Decision Sciences Institute (DSI) National Meeting, (November)
37. Pathak, Surya, Dilts DM, and Biswas, Gautam, (2004) “Simulating Growth Dynamics in Complex Adaptive Supply Networks,” Winter Simulation Conference (December), pp: 774-782.
38. Belser, Duncan and Dilts DM (2004) “A Research-Based Approach to Investment Decisions in Healthcare Information Technology: The VCBH ROI Model,” DSI National Meeting (November).
39. Dilts DM and Baik, Y (2003) “Impact of Decision Speed in the Control of an Extended Enterprise,” DSI National Meeting, (November).
40. Adamson, I. and Dilts DM, (2001) “Measurement of Accounting System Complexity at the Design Level”, Proceedings of the DSI National Meeting,.
41. Dilts DM (1999) “Evaluation of Tools for Use In Determining SME Readiness for Next Generation Manufacturing, Alliance of Manufacturers and Exporters of Canada, 35 pages. (Technical Report)
42. Dilts DM (1998) “Survey of Executive Perspectives on Extended, Integrated Enterprises,” Consortium for Advanced Manufacturing – International Integrated Enterprise Technical Report, 13 pages.
43. Khamalah, J. and Dilts DM (1997) “Predicting Patient Resource Needs: A Methodology for Ambulatory Care,” Proceedings of DSI National Meeting,, pp. 1464-1466.
44. Dilts DM and Lyth, DM, (1990) “A Longitudinal Study of Leading Edge Shop Floor Control Systems,” Proceedings of the DSI National Meeting, pp. 77-79.
45. Dilts DM and Turowski, DG, (1989) “Incorporating Strategic Knowledge Within Investment Justification,” Proceedings of the 8th Annual Conference of the Operations Management Association, pp. 37-46.
46. Dilts DM and Turowski, DG, (1989) “Strategic Investment Justification of Advanced Manufacturing Technology Using a Knowledge-Based System,” 3rd Int. Conf. on Expert Systems & the Leading Edge in Production & Operations Management, pp. 192-206.
47. Dilts DM and Russell, GW (1989) “Measuring External Failure: Accounting for the Four Costs of External Failure,” Proceedings of the 43rd Annual Quality Congress, American Society for Quality Control, pp. 317-322.
48. Dilts DM and Wu, W, (1989) “Knowledge-Based Systems for Integrating Computer Integrated Manufacturing Data Bases,” Third International Conference on Expert Systems and the Leading Edge in Production & Operations Management, pp. 255-268.
49. Dilts DM (1988) “Integration of Computer Integrated Manufacturing Data Bases Using Artificial Intelligence,” Second International Conference on Expert Systems and the Leading Edge in Production & Operations Management, pp. 277-284.
50. Dilts DM and Rowland, RL, (1985) “Expert Systems for Capacity Management,” Proceedings of the American Institute of Decision Sciences, pp. 165‑167.
51. Dilts D, Cheng S, Cronin K, Fearn P, Feuer E, Friedman S, Kosary C, Lam C, Mariotto A, Negoita S, Petkov V, Penberthy L (2017) “An Innovative Approach to Developing the SEER-Wide Quality Audit Plan,” North American Association of Central Cancer Registries (NAACCR), June.
52. Parker C, Millar JL, Dilts DM, Jefford M, Wolfe R, Snyder R (2015) “A randomized control trial (RCT) to improve enrolment to cancer clinical trials” J Clin Oncol 33:15s (suppl; abstr: 6514).
53. Cheng SK, Hirsch BR, Califf RM, Tasneem A, Schulman KA, Abernethy AP, Dilts DM (2012) “Geographic and network analysis of oncology trials: Portfolio assessment of ClinicalTrial.gov” J Clin Oncol 30:15s (suppl; abstr 6047).
54. Hirsch BR, Mitchell A, Cheng SK, Califf RM, Tasneem A, Dilts DM, Abernethy AP (2012) “Improving the impact of clinical research: A systematic analysis of kidney cancer trials” J Clin Oncol 30:15s (suppl; abstr 6051).
55. Hirsch BR, Califf RM, Cheng SK, Tasneem A, Chiswell K, Horton JR, Schulman KA, Dilts DM, Abernethy AP (2012) “The State of the Oncology Clinical Trials Portfolio: Insights from ClinicalTrial.gov”, Society of Clinical Trials Meeting (May).
56. Kitterman D, Cheng SK, Dilts DM, Orwoll ES (2011) “An etiologic survey of factors that contribute to non-enrolling clinical studies,” NCRR Clinical Research Management Workshop, Bethesda MD (Jun)
57. Massett H, Parreco LK, Padberg RM, Richmond E, Dilts DM (2011) “AccrualNet: a novel approach to addressing clinical trial accruals through a knowledge-based, community of practice platform,” J Clin Oncol 29 (suppl; abstr e16621)
58. Stahl DC, Cheng SK, Lee E, Dilts DM (2011) “Benchmarking of oncology clinical trial metrics across AACI member centers,” J Clin Oncol 29 (suppl; abstr e16613)
59. Cheng S, Dietrich, M, Finnigan S, Dilts DM (2010) “Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials” J Clin Oncol 28:15s (suppl; abstr 6001)
60. Dilts DM, Massett H (2010) Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial”. American Society of Clinical Oncology, Chicago, IL. (Abstract #e16505)
61. Cheng S, Dietrich, M, Finnigan S, Sandler A, Crites J, Ferranti L, Wu A, Dilts DM (2009) “A Sense of Urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies,” J Clin Oncol 27:15s (suppl; abstr 6509)
62. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, and Wu A (2008), “Are Cancer Clinical Trials in the USA Going the Way of Oldsmobile?,” Production and Operations Management Society 2008.
63. Hackett, Sean M and Dilts DM (2006) “Real options and the option to incubate: an exploratory study of the process of business incubation,” Academy of Management Annual Meeting, Atlanta, GA.
64. Johnson, Joshua H and Dilts DM (2006) “Acquire and Forget: The conflict of information acquisition and organizational memory in the development of radical innovations,” AMA Winter Marketing Educators’ Conference.
65. Dilts DM (2005) “Practice Variation: The Achilles’ Heel in Quality Cancer Care,” Journal of Clinical Oncology, 23:17(Sept 1): 5881-2 (invited) PMID: 16087953
66. Xie, Bin and Dilts DM (2005) “Effects of Patient Obtained Medical Information (POMI) on Healthcare Services Utilization in U.S. Counties,” Academy Health Annual Research and Health Policy Conference, Boston (Poster Presentation).
67. Piasecki JK, Calhoun E, Engelberg J, Rice W, Dilts DM, Belser D, Aronsky D, Jones I, Mason D, Stead B, (2005) “Computerized provider order entry in the emergency department: pilot evaluation of a return on investment analysis instrument,” AMIA Symposium Proceedings, p. 1081. PMID: 16779368
68. Inukai, Tsuyshi and Dilts DM (2004) “The Impact of Technological Innovation Type on Strategic Alliances for New Product Development,” Academy of Management National Conference.
69. Dilts DM and Chuang, R. JW. (1997) “Perceptions of Service Quality in Telemedicine” Academy of Management Annual Meeting.
70. (2015) “Observations on Clinical Research: Some Ideas for NHLBAC”, National Heart, Lung Blood Advisory Council, NIH,(June).
71. (2015) “Going Beyond the Norm: Some Ideas for the British Columbia Cancer Agency” British Columbia Cancer Agency Retreat, Vancouver, BC(May)
72. (2015) “Value-based Structures: Centralization and Decentralization”, NIH-Association of Biomolecular Resource Facilities Workshop on Enhancing Efficiency of Research Core Facilities, St Louis, MO(Mar)
73. (2014) “The Promise and Perils in Clinical Trials,” Monash University, Melbourne, Australia(August, presented twice)
74. (2013) “Prioritizing and Measuring Clinical Research,” NIH Clinical Research Subcommittee, Bethesda, MD(Sept).
75. (2013) “A Model for Evaluating the Efficiency and Effectiveness of Clinical Research,” Medical Executive Committee, NIH, Bethesda MD(May).
76. (2013) “Process Improvement: Linking Improvement to Strategy,” Oregon Health Financial Manager’s Association, Portland, OR(Feb)
77. (2011) “Clinical Research as a Complex Adaptive System,” Arizona State University Institute for Complexity, Phoenix, AZ(Mar)
78. (2010) “Clinical Trial and Regulatory Process Mapping, the Clinical Trials and Regulatory Pathways Working Group at the Center for Global Development,(Oct)
79. (2010) “The Science of Trial Selection, Infrastructure, and Operations,” NCI-ASCO Symposium on Accruals, Chicago IL(Apr)
80. (2009) “The Need for Operations Management in Healthcare: The Case of Oncology Clinical Trials,” Distinguished Lecture, Supply Chain Management Area, Sir Wilfrid Laurier University(Dec)
81. (2009) “Envisioning the future: Lessons from the past(& present) in Oncology Clinical Trials”, keynote speech to Johns Hopkins Sidney Kimmel Comprehensive Cancer Center strategic retreat, Baltimore MD(Mar)
82. COG Orgranizational Redesign
83. Behringer B, Omohundro E, Boswell D, Evans D and Ferranti L. The Tennessee Department of Health WORKshops on the Use of Secondary Data for Community Health Assessment, 2012. Preventing Chronic Disease. (2014). 11:130206. DOI: http://dx.doi.org/10.5888/pdc.11.130260.
84. L Ferranti, PhD., Principal Investigator and V. Pinkney. Tennessee Disparity and Diversity in Public Health, “Using Data from the 2012-2013 Community Health”. CDC Poster presentation National Meeting -Assessment to Make a Difference. (April 2013).
85. Ferranti L. Vanderbilt University, School of Global Health, “The Use of Medical Registries?”. (2012)
86. Ferranti, L; “A Systematic Review: Pediatric Asthma Compliance and Outcomes.” Vanderbilt University School of Nursing Research Day, August 2002. (2nd place award)
87. Rosow CE, DiBiase PM, Zaslavsky A, Burch L. “Propofol vs. thiopental in in-patients: Comparison of recovery after general anesthesia” Proceedings of the Annual Meeting of the American Society of Anesthesiologists, Anesthesiology 1993; 79 (3): A-336.
88. Rosow CE, Burch L. “Bispectral Analysis for Monitoring Hypnotic Drug Effects” (submitted) 1999.
89. Ferranti, L. “What is a Medical Registry?” Unpublished paper presented at Owen Graduate School of Management, Vanderbilt University, Nashville, TN, March, 2002
90. Ferranti, L. “Pediatric Asthma Compliance and Outcomes”. Paper presented at Vanderbilt University School of Nursing, Annual Research Day Nashville, TN, August, 2001.
91. Ferranti, L. “School Based Health Clinics: Their Advantages and the Challenges They Face.” Unpublished paper presented at Owen Graduate School of Management, Vanderbilt University, Nashville, TN, April,2001.
92. Ferranti, L. Internet Pharmaceutical Sales. Unpublished paper presented at Owen Graduate School of Management,
93. Coyne, T. & Ferranti, L. Health Insurance Portability and Accountability Act. Unpublished paper presented at Vanderbilt University School of Nursing, Nashville, December, 2000.
2. Dilts DM, Zell A, Orwoll E (2015) “A Novel Approach to Measuring Efficiency of Scientific Research Projects: Data Envelopment Analysis.” Clinical and Translational Science. 8(5):495-501. PMID:26243147
3. Dilts DM, (2013) “A 3+1 Level Evaluation Model for CRM”, Evaluation & the Health Professions 36(4):464-477 PMID: 23908383.
4. Grazier KL, Trochim W, Dilts DM, Kirk R (2013) “Estimating Return on Investment in Translational Research: Methods and Protocols”, Evaluation & the Health Professions, 36(4):478-491. PMID: 23925706
5. Hirsh BR, Califf RM, Cheng SK, Tasneem A, Horton J, Chriswell K, Schulman KA, Dilts DM, and Abernethy AP (2013) “Design of Oncology Clinical Trials: Insights from a Systematic Analysis of ClinicalTrials.gov,” JAMA Internal Medicine, 173(11):972-979. PMID:23699837.
6. Dilts DM, Rosenblum D, and Trochim WM, (2012) “A Virtual National Laboratory for Re-Engineering Clinical and Translational Science,” Science Translational Medicine, 4(118) 118cm2. PMID:22277966.
7. Massett H, Parreco LK, Padberg RM, Richmond ES, Rienzo, ME, Ryan Leonard CE, Quesenbery W, Killam HW, Johnson, and Dilts DM (2011) “AccrualNet: Addressing low accrual via a knowledge-based, community of practice Platform,” J of Oncology Practice, 7(6): e32-e39. PMID:22379429.
8. Kitterman, D, Cheng, S, Dilts DM, and Orwoll, ES, (2011) “The Prevalence and Economic Impact of Low Enrolling Clinical Studies at an Academic Medical Center,” Academic Medicine 86(11): 1360-66. PMID:21952064
9. Cheng S, Dietrich M, Dilts DM (2011) “Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP Sponsored Clinical Trials,” Clin Cancer Res. 17: 1947-55. PMID:21447723
10. Dilts DM, Cheng S, Crites JS, Sander AB, Doroshow J, (2010) “Phase III Clinical Trial Development: A Process of Chutes & Ladders,” Clin Cancer Res. 16(22): 5381-89. PMID:21062928
11. Cheng S, Dietrich M, Dilts DM (2010) “A Sense of Urgency: Evaluating the Link Between Clinical Trial Development Time and the Accrual Performance of CTEP-Sponsored Studies,” Clin Cancer Res, 16(22): 5557-63. PMID:21062929
12. Dilts DM, Sander AB, Cheng S, Crites J, Ferranti L, Wu, A, Finnigan S., Friedman S, Mooney M, Abrams J, (2009) “The Steps and Time to Process Phase III Clinical Trials at the Cancer Therapy Evaluation Program,” J of Clin Oncol, 27(11): 1761-6. PMID: 19255315
13. Dilts DM, Ridner, SH, Franco A, Murphy B, (2009) “Patients with Cancer and E-mail: Implications for Clinical Communication,” J of Supportive Care in Cancer, 17(8): 1049-1056. PMID:19050941.
14. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, Wu A, Gray R, MacDonald J, Marinucci D, Comis R. (2008) “Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Group,” Clin Cancer Res, 14(11):3427-33. PMID: 18519773
15. Dilts DM and Sandler AB, (2006) “The “Invisible” Barriers to Clinical Trials: The impact of Structural, Infrastructural, and Procedural Barriers to Opening Oncology Clinical Trials,” J Clin Oncol, 24(28): 4545-52. PMID: 17008693
16. Dilts DM, Sandler AB, Baker M, Cheng S, George SL, Karas KS, McGuire S, Menon G, Reusch J, Sawyer D, Scoggins M, Wu A, Zhou K, Schilsky RL (2006) “Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of the Cancer Leukemia Group B (CALGB), J Clin Oncol, 24(28): 4553-57. PMID: 17008694
17. Xie Bin, Dilts DM and Shor, M (2006) “The Physician-Patient Relationship: The Impact of Patient-Obtained Medical Information,” Health Econ, 15(8): 813-833. PMID: 16550612
18. Hackett SM, and Dilts DM (2004) “A Real Options-Driven Theory of Business Incubation,” J of Technology Transfer, 29(1): 41-54. [Reprinted in “Recent Development in the Economics of Science and Innovation”, editor: A. N Link and C. Antonelli, 2013]
19. Zhang Yong and Dilts DM, (2004) “System Dynamics of Supply Chain Network Organization Structure,” Information Systems and e-Business Management: Special Issue on Supply Chain Management, 2:187-206.
20. Khamalah J and Dilts DM (2001) “Determining Resource Needs for Specialty Ambulatory Clinics using Classification/Assignment Methods,” Int J of Operations and Quantitative Management, 7(4): 241-256.
21. Dilts DM (2001) “Functional Manager’s Perceptions of Performance Measurements: The Impact of Industry and Firm Level Characteristics,” Int J of Agile Manufacturing, 4(1): 17-28.
22. Dilts DM and Khamalah J (1999) “A comparison of ordinal analysis techniques in medical resource usage research,” Electronic Notes in Discrete Mathematics. (http://www.elsevier.com/cas/tree/store/ disc/sub/endm/store/disc2/disc2005.ps) (invited), 2: 51-68
23. Hill T, Menda R, and Dilts DM. (1998) “Using Product Profiling to Illustrate Manufacturing-Marketing Misalignment,” Interfaces, 28(4): 47-63.
24. Menda, R, and Dilts DM, (1997) “The Manufacturing Strategy Formulation Process: Linking Multifunctional Viewpoints,” J of Operations Management, 15(4): 223-41.
25. Doughty MJ, Dilts DM, and Lyle, WM, (1996) “Impact of Using Weighted Versus Unweighted Measures for Assessments of Optometry Faculty Productivity in Research,” J of the Am Optometric Association, 67(7): 410-420. PMID: 8888867
26. Khamalah J, Dilts DM, and Plotkin AD, (1995) “Using Cluster Analysis For Medical Resource Decision Making,” Medical Decision Making, 15(4, Oct-Dec): 333-347. PMID: 8544677
27. Dilts DM, Khamalah J, and Plotkin AD, (1994) “Clinical Low Vision Resource Usage Prediction,” Optometry & Vision Science, 71(7): 422-436. PMID: 7970557
28. Wu W, and Dilts DM (1992) “Integrating Diverse CIM Data Bases: The Role of Natural Language Interface,” IEEE Trans on Systems, Man, & Cybernetics, 22(6): 1331-47.
29. Dilts DM and Wu W, (1991) “Using Knowledge-Based Technology to Integrate CIM Databases,” IEEE Trans on Knowledge & Data Engineering, 3(2): 237-45.
30. Dilts DM, Boyd N, and Whorms H, (1991) “The Evolution of Control Architectures for Automated Manufacturing Systems,” J of Manufacturing Systems, 10(1): 79-93.
31. Yee, D, (34 others) (2012) “Adaptive trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development,” J of Clin Onc, Letter, Dec 20; 30(36): 4584-6. doi: 10.1200/JCO.2012.44.1022
32. Dilts DM, Cheng SK (2012) “The Importance of Doing Trials Right While Doing The Right Trials,” Clin Cancer Res, 18(1):3-5. PMID:22072734
33. Dilts DM, (2010) “US cancer trials may go the way of the Oldsmobile,” Nature Medicine 16(5):21. PMID:20526311
34. Dilts DM, (2010) “An Early Warning: Ailing Canary in the Mine,” J Clin Onc, 28(24): 3799-800. PMID: 20644096
35. Ferranti, L, Cheng S, and Dilts DM (2010) “On Baseball, Medical Decision Making and Innumeracy,” Chapter 18 in Decision Making Wiley, (editors: P Nutt and D Wilson).
36. Pathak SD and Dilts DM (2006) “Investigating evolution in the US healthcare industry,” Decision Sciences Institute (DSI) National Meeting, (November)
37. Pathak, Surya, Dilts DM, and Biswas, Gautam, (2004) “Simulating Growth Dynamics in Complex Adaptive Supply Networks,” Winter Simulation Conference (December), pp: 774-782.
38. Belser, Duncan and Dilts DM (2004) “A Research-Based Approach to Investment Decisions in Healthcare Information Technology: The VCBH ROI Model,” DSI National Meeting (November).
39. Dilts DM and Baik, Y (2003) “Impact of Decision Speed in the Control of an Extended Enterprise,” DSI National Meeting, (November).
40. Adamson, I. and Dilts DM, (2001) “Measurement of Accounting System Complexity at the Design Level”, Proceedings of the DSI National Meeting,.
41. Dilts DM (1999) “Evaluation of Tools for Use In Determining SME Readiness for Next Generation Manufacturing, Alliance of Manufacturers and Exporters of Canada, 35 pages. (Technical Report)
42. Dilts DM (1998) “Survey of Executive Perspectives on Extended, Integrated Enterprises,” Consortium for Advanced Manufacturing – International Integrated Enterprise Technical Report, 13 pages.
43. Khamalah, J. and Dilts DM (1997) “Predicting Patient Resource Needs: A Methodology for Ambulatory Care,” Proceedings of DSI National Meeting,, pp. 1464-1466.
44. Dilts DM and Lyth, DM, (1990) “A Longitudinal Study of Leading Edge Shop Floor Control Systems,” Proceedings of the DSI National Meeting, pp. 77-79.
45. Dilts DM and Turowski, DG, (1989) “Incorporating Strategic Knowledge Within Investment Justification,” Proceedings of the 8th Annual Conference of the Operations Management Association, pp. 37-46.
46. Dilts DM and Turowski, DG, (1989) “Strategic Investment Justification of Advanced Manufacturing Technology Using a Knowledge-Based System,” 3rd Int. Conf. on Expert Systems & the Leading Edge in Production & Operations Management, pp. 192-206.
47. Dilts DM and Russell, GW (1989) “Measuring External Failure: Accounting for the Four Costs of External Failure,” Proceedings of the 43rd Annual Quality Congress, American Society for Quality Control, pp. 317-322.
48. Dilts DM and Wu, W, (1989) “Knowledge-Based Systems for Integrating Computer Integrated Manufacturing Data Bases,” Third International Conference on Expert Systems and the Leading Edge in Production & Operations Management, pp. 255-268.
49. Dilts DM (1988) “Integration of Computer Integrated Manufacturing Data Bases Using Artificial Intelligence,” Second International Conference on Expert Systems and the Leading Edge in Production & Operations Management, pp. 277-284.
50. Dilts DM and Rowland, RL, (1985) “Expert Systems for Capacity Management,” Proceedings of the American Institute of Decision Sciences, pp. 165‑167.
51. Dilts D, Cheng S, Cronin K, Fearn P, Feuer E, Friedman S, Kosary C, Lam C, Mariotto A, Negoita S, Petkov V, Penberthy L (2017) “An Innovative Approach to Developing the SEER-Wide Quality Audit Plan,” North American Association of Central Cancer Registries (NAACCR), June.
52. Parker C, Millar JL, Dilts DM, Jefford M, Wolfe R, Snyder R (2015) “A randomized control trial (RCT) to improve enrolment to cancer clinical trials” J Clin Oncol 33:15s (suppl; abstr: 6514).
53. Cheng SK, Hirsch BR, Califf RM, Tasneem A, Schulman KA, Abernethy AP, Dilts DM (2012) “Geographic and network analysis of oncology trials: Portfolio assessment of ClinicalTrial.gov” J Clin Oncol 30:15s (suppl; abstr 6047).
54. Hirsch BR, Mitchell A, Cheng SK, Califf RM, Tasneem A, Dilts DM, Abernethy AP (2012) “Improving the impact of clinical research: A systematic analysis of kidney cancer trials” J Clin Oncol 30:15s (suppl; abstr 6051).
55. Hirsch BR, Califf RM, Cheng SK, Tasneem A, Chiswell K, Horton JR, Schulman KA, Dilts DM, Abernethy AP (2012) “The State of the Oncology Clinical Trials Portfolio: Insights from ClinicalTrial.gov”, Society of Clinical Trials Meeting (May).
56. Kitterman D, Cheng SK, Dilts DM, Orwoll ES (2011) “An etiologic survey of factors that contribute to non-enrolling clinical studies,” NCRR Clinical Research Management Workshop, Bethesda MD (Jun)
57. Massett H, Parreco LK, Padberg RM, Richmond E, Dilts DM (2011) “AccrualNet: a novel approach to addressing clinical trial accruals through a knowledge-based, community of practice platform,” J Clin Oncol 29 (suppl; abstr e16621)
58. Stahl DC, Cheng SK, Lee E, Dilts DM (2011) “Benchmarking of oncology clinical trial metrics across AACI member centers,” J Clin Oncol 29 (suppl; abstr e16613)
59. Cheng S, Dietrich, M, Finnigan S, Dilts DM (2010) “Early indicators of accrual success: Time-to-first-patient and accrual performance at an anticipated enrollment milestone-A study of NCI-CTEP-sponsored clinical trials” J Clin Oncol 28:15s (suppl; abstr 6001)
60. Dilts DM, Massett H (2010) Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial”. American Society of Clinical Oncology, Chicago, IL. (Abstract #e16505)
61. Cheng S, Dietrich, M, Finnigan S, Sandler A, Crites J, Ferranti L, Wu A, Dilts DM (2009) “A Sense of Urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies,” J Clin Oncol 27:15s (suppl; abstr 6509)
62. Dilts DM, Sandler AB, Cheng S, Crites J, Ferranti L, and Wu A (2008), “Are Cancer Clinical Trials in the USA Going the Way of Oldsmobile?,” Production and Operations Management Society 2008.
63. Hackett, Sean M and Dilts DM (2006) “Real options and the option to incubate: an exploratory study of the process of business incubation,” Academy of Management Annual Meeting, Atlanta, GA.
64. Johnson, Joshua H and Dilts DM (2006) “Acquire and Forget: The conflict of information acquisition and organizational memory in the development of radical innovations,” AMA Winter Marketing Educators’ Conference.
65. Dilts DM (2005) “Practice Variation: The Achilles’ Heel in Quality Cancer Care,” Journal of Clinical Oncology, 23:17(Sept 1): 5881-2 (invited) PMID: 16087953
66. Xie, Bin and Dilts DM (2005) “Effects of Patient Obtained Medical Information (POMI) on Healthcare Services Utilization in U.S. Counties,” Academy Health Annual Research and Health Policy Conference, Boston (Poster Presentation).
67. Piasecki JK, Calhoun E, Engelberg J, Rice W, Dilts DM, Belser D, Aronsky D, Jones I, Mason D, Stead B, (2005) “Computerized provider order entry in the emergency department: pilot evaluation of a return on investment analysis instrument,” AMIA Symposium Proceedings, p. 1081. PMID: 16779368
68. Inukai, Tsuyshi and Dilts DM (2004) “The Impact of Technological Innovation Type on Strategic Alliances for New Product Development,” Academy of Management National Conference.
69. Dilts DM and Chuang, R. JW. (1997) “Perceptions of Service Quality in Telemedicine” Academy of Management Annual Meeting.
70. (2015) “Observations on Clinical Research: Some Ideas for NHLBAC”, National Heart, Lung Blood Advisory Council, NIH,(June).
71. (2015) “Going Beyond the Norm: Some Ideas for the British Columbia Cancer Agency” British Columbia Cancer Agency Retreat, Vancouver, BC(May)
72. (2015) “Value-based Structures: Centralization and Decentralization”, NIH-Association of Biomolecular Resource Facilities Workshop on Enhancing Efficiency of Research Core Facilities, St Louis, MO(Mar)
73. (2014) “The Promise and Perils in Clinical Trials,” Monash University, Melbourne, Australia(August, presented twice)
74. (2013) “Prioritizing and Measuring Clinical Research,” NIH Clinical Research Subcommittee, Bethesda, MD(Sept).
75. (2013) “A Model for Evaluating the Efficiency and Effectiveness of Clinical Research,” Medical Executive Committee, NIH, Bethesda MD(May).
76. (2013) “Process Improvement: Linking Improvement to Strategy,” Oregon Health Financial Manager’s Association, Portland, OR(Feb)
77. (2011) “Clinical Research as a Complex Adaptive System,” Arizona State University Institute for Complexity, Phoenix, AZ(Mar)
78. (2010) “Clinical Trial and Regulatory Process Mapping, the Clinical Trials and Regulatory Pathways Working Group at the Center for Global Development,(Oct)
79. (2010) “The Science of Trial Selection, Infrastructure, and Operations,” NCI-ASCO Symposium on Accruals, Chicago IL(Apr)
80. (2009) “The Need for Operations Management in Healthcare: The Case of Oncology Clinical Trials,” Distinguished Lecture, Supply Chain Management Area, Sir Wilfrid Laurier University(Dec)
81. (2009) “Envisioning the future: Lessons from the past(& present) in Oncology Clinical Trials”, keynote speech to Johns Hopkins Sidney Kimmel Comprehensive Cancer Center strategic retreat, Baltimore MD(Mar)
82. COG Orgranizational Redesign
83. Behringer B, Omohundro E, Boswell D, Evans D and Ferranti L. The Tennessee Department of Health WORKshops on the Use of Secondary Data for Community Health Assessment, 2012. Preventing Chronic Disease. (2014). 11:130206. DOI: http://dx.doi.org/10.5888/pdc.11.130260.
84. L Ferranti, PhD., Principal Investigator and V. Pinkney. Tennessee Disparity and Diversity in Public Health, “Using Data from the 2012-2013 Community Health”. CDC Poster presentation National Meeting -Assessment to Make a Difference. (April 2013).
85. Ferranti L. Vanderbilt University, School of Global Health, “The Use of Medical Registries?”. (2012)
86. Ferranti, L; “A Systematic Review: Pediatric Asthma Compliance and Outcomes.” Vanderbilt University School of Nursing Research Day, August 2002. (2nd place award)
87. Rosow CE, DiBiase PM, Zaslavsky A, Burch L. “Propofol vs. thiopental in in-patients: Comparison of recovery after general anesthesia” Proceedings of the Annual Meeting of the American Society of Anesthesiologists, Anesthesiology 1993; 79 (3): A-336.
88. Rosow CE, Burch L. “Bispectral Analysis for Monitoring Hypnotic Drug Effects” (submitted) 1999.
89. Ferranti, L. “What is a Medical Registry?” Unpublished paper presented at Owen Graduate School of Management, Vanderbilt University, Nashville, TN, March, 2002
90. Ferranti, L. “Pediatric Asthma Compliance and Outcomes”. Paper presented at Vanderbilt University School of Nursing, Annual Research Day Nashville, TN, August, 2001.
91. Ferranti, L. “School Based Health Clinics: Their Advantages and the Challenges They Face.” Unpublished paper presented at Owen Graduate School of Management, Vanderbilt University, Nashville, TN, April,2001.
92. Ferranti, L. Internet Pharmaceutical Sales. Unpublished paper presented at Owen Graduate School of Management,
93. Coyne, T. & Ferranti, L. Health Insurance Portability and Accountability Act. Unpublished paper presented at Vanderbilt University School of Nursing, Nashville, December, 2000.